Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 18/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 18/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17269423 | 0.77 | PDE3B (0.56) | PDE3BPDE3A | |
| SCHEMBL10810836 | 0.75 | PDE3B (0.71) | PDE3BPDE3A | |
| SCHEMBL18238083 | 0.74 | BRD4 (0.32) | — | |
| SCHEMBL2739294 | 0.73 | PDE3B (0.59) | PDE3BPDE3AMAPK1KDM5A | |
| SCHEMBL24996942 | 0.72 | PDE3B (0.43) | PDE3BPDE3AMAPK1 | |
| SCHEMBL12946582 | 0.71 | PDE3B (0.36) | PDE3BPDE3A | |
| SCHEMBL18237685 | 0.69 | — | — | |
| SCHEMBL18238084 | 0.69 | PDE3A (0.40) | PDE3BPDE3AMAPK1 | |
| SCHEMBL18238082 | 0.68 | METAP2 (0.37) | — | |
| SCHEMBL18237952 | 0.66 | CYP1A2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PDE3B 1701/4885PDE3A 1396/4885MAPK1 80/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PDE3B 1701/4885PDE3A 1396/4885MAPK1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.